-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
The latest news on the Chinese drug clinical trial registration and information disclosure platform, Shengnuo Pharmaceutical's new class 1 chemical drug X842 capsule has started a phase 3 clinical trial for the treatment of reflux esophagitis.
Screenshot source: www.
Screenshot source: www.
According to public information released by Ciclus Pharma earlier, X842 has a longer half-life than PPI, and uses a different mechanism of action to regulate and control the release of gastric acid.
The launch in China this time is a multi-center, randomized, double-blind, double-dummy, and positive-drug parallel-controlled Phase 3 clinical study evaluating X842 capsules in patients with reflux esophagitis.
Gastroesophageal reflux disease is a common digestive system disease characterized by reflux of gastric acid from the stomach to the esophagus, causing severe pain and mucosal erosion.
It is worth mentioning that the Phase 1 clinical trials of X842 in Sweden and China were completed in February 2018 and September 2019 respectively.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
Reference
[1] China Drug Clinical Trial Registration and Information Disclosure Platform.
[1] China Drug Clinical Trial Registration and Information Disclosure Platform.
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
